New drug targets Hard-to-Treat cancers with specific mutation
NCT ID NCT02381886
First seen Nov 11, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-phase study tests an experimental drug called IDH305 in people with advanced cancers that have a specific genetic change (IDH1R132 mutation). The main goals are to find the safest dose and to check for side effects. About 166 adults with various advanced tumors are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES THAT HARBOR IDHR132 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Columbia University Medical Center- New York Presbyterian Onc Dept.
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute SC (1)
Boston, Massachusetts, 02115, United States
-
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55
Rotterdam, 3075 EA, Netherlands
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Parkville, Victoria, 3050, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Rotterdam, South Holland, 3015 GD, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.